At the news
? BULLISHIMPACT 8/10 6-K filed Apr 20, 2026 at 06:02 ET
argenx announced positive Phase 3 data from the ADAPT OCULUS and ADAPT SERON trials showing VYVGART's efficacy in ocular and seronegative myasthenia gravis, along with supportive data in CIDP. The company plans to submit a supplemental Biologics License Application (sBLA) for ocular MG and already has priority review for seronegative gMG, expanding VYVGART's potential market. Real-world data also support switching from IVIg to VYVGART Hytrulo in CIDP.
- Phase 3 ADAPT OCULUS study met primary endpoint (p=0.012) in ocular myasthenia gravis (oMG), showing statistically significant improvement in MGII PRO ocular scores at Week 4 vs placebo
- ADAPT SERON trial supports VYVGART's efficacy in AChR-Ab seronegative gMG (including MuSK+, LRP4+, triple seronegative), with FDA priority review granted and PDUFA date of May 10, 2026
- ADAPT Jr trial shows consistent MG-ADL improvements in adolescents with gMG
- ADHERE post hoc analysis shows 87.5% of treatment-naïve CIDP patients achieved early clinical benefit with VYVGART Hytrulo, median time to response 39.5 days
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access